Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV LID cp ΔM2-2
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
RSV LID cp ΔM2-2 is a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is engineered from the RSV Low Infectivity (LID) backbone and is attenuated through two primary modifications: the deletion of the M2-2 gene (ΔM2-2), which encodes an RNA regulatory protein involved in the balance between viral transcription and replication, and the inclusion of five cold-passage (cp) mutations. Administered intranasally as nose drops, the vaccine was designed to prevent RSV lower respiratory tract disease in seronegative infants and young children aged 6 to 24 months. However, Phase I clinical results indicated that the candidate was over-attenuated, resulting in low infectivity and insufficient immunogenicity, leading to the discontinuation of its development.
- Other names
- RSV LID cp DeltaM2-2LID cp DeltaM2-2 Vaccinerecombinant live-attenuated respiratory syncytial virus vaccine LID cp ΔM2-2
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV LID cp ΔM2-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV LID cp ΔM2-2.